Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia

Background: Autosomal dominant hypercholesterolemia (ADH) is due to deleterious variants in LDLR, APOB, or PCSK9 genes. Double heterozygote for these genes induces a more severe phenotype. More recently, a new causative variant of heterozygous ADH was identified in APOE. Here we study the phenotype of 21 adult patients, double heterozygotes for rare LDLR and rare APOE variants (LDLR+APOE) in a national wide French cohort. Methods: LDLR, APOB, PCSK9, and APOE genes were sequenced in 5743 probands addressed for ADH genotyping. The lipid profile and occurrence of premature atherosclerotic cardiovascular diseases were compared between the LDLR+APOE carriers (n=21) and the carriers of the same LDLR causative variants alone (n=22). Results: The prevalence of LDLR+APOE carriers in this French ADH cohort is 0.4%. Overall, LDL (low-density lipoprotein)-cholesterol concentrations were 23% higher in LDLR+APOE patients than in LDLR patients (9.14±2.51 versus 7.43±1.59 mmol/L, P=0.0221). When only deleterious or probably deleterious variants were considered, the LDL-cholesterol concentrations were 46% higher in LDLR+APOE carriers than in LDLR carriers (10.83±3.45 versus 7.43±1.59 mmol/L, P=0.0270). Two patients exhibited a homozygous familial hypercholesterolemia phenotype (LDL-cholesterol >13 mmol/L). Premature atherosclerotic cardiovascular disease was more common in LDLR+APOE patients than in LDLR carriers (70% versus 30%, P=0.026). Conclusions: Although an incomplete penetrance should be taken into account for APOE variant classification, these results suggest an additive effect of deleterious APOE variants on ADH phenotype highlighting the relevance of APOE sequencing.

[1]  J. Ferrières,et al.  APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia , 2022, International journal of molecular sciences.

[2]  J. Knowles,et al.  The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification , 2021, medRxiv.

[3]  T. Kene,et al.  Reference intervals of common clinical biochemistry analytes in young Nigerian adults , 2021, PloS one.

[4]  P. Moulin,et al.  Development of a new expanded next‐generation sequencing panel for genetic diseases involved in dyslipidemia , 2020, Clinical genetics.

[5]  D. Ledbetter,et al.  Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders , 2019, Nature Communications.

[6]  César Martín,et al.  Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. , 2019, Atherosclerosis.

[7]  M. Krempf,et al.  High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. , 2018, Atherosclerosis.

[8]  A. Carrié,et al.  Familial hypercholesterolemia: experience from France , 2018, Current opinion in lipidology.

[9]  G. Peloso,et al.  New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia , 2018, Scientific Reports.

[10]  G. Luc,et al.  Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia? , 2018, European Journal of Human Genetics.

[11]  I. Nolte,et al.  Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants , 2017 .

[12]  M. Bourbon,et al.  Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. , 2017, Atherosclerosis.

[13]  B. Arsenault,et al.  Does lifestyle contribute to disease severity in patients with inherited lipid disorders? , 2017, Current opinion in lipidology.

[14]  S. Humphries,et al.  The UCL low-density lipoprotein receptor gene variant database: pathogenicity update , 2016, Journal of Medical Genetics.

[15]  K. Berge,et al.  Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene , 2016, Molecular Genetics and Metabolism Reports.

[16]  P. Slagboom,et al.  INTERPLAY BETWEEN LIPIDS AND THE EPIGENOME : EPIDEMIOLOGICAL APPROACHES , 2016 .

[17]  R. Wintjens,et al.  Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France[S] , 2016, Journal of Lipid Research.

[18]  S. Azar,et al.  Variable expressivity and co‐occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy , 2016, Molecular genetics & genomic medicine.

[19]  I. Mcdowell,et al.  Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. , 2015, Atherosclerosis.

[20]  E. Ros,et al.  Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study. , 2015, Atherosclerosis.

[21]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  César Martín,et al.  The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. , 2016, The Journal of clinical endocrinology and metabolism.

[23]  J. Borén,et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[24]  D. Blom,et al.  Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E , 2014, Critical reviews in clinical laboratory sciences.

[25]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[26]  R. Fresa,et al.  Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. , 2013, Atherosclerosis.

[27]  Mathilde Varret,et al.  Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation , 2013, Human mutation.

[28]  S. G. Hadfield,et al.  Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project , 2010, Clinical genetics.

[29]  G. Moretto,et al.  Structural and phylogenetic approaches to assess the significance of human Apolipoprotein E variation. , 2006, Molecular genetics and metabolism.

[30]  R. Fresa,et al.  Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. , 2006, Atherosclerosis.

[31]  I. Kema,et al.  Discovery and consequences of apolipoprotein-ε 3Groningen: a G-insertion in codon 95/96 that is predicted to cause a premature stop codon , 2005, Annals of clinical biochemistry.

[32]  G. D. De Stefano,et al.  Genetic Variation at Apolipoprotein E Locus in Ethiopia: An E5 Variant Corresponds to Two Different Mutant Alleles: E*5 (Glu212Lys) and E*5 (Gln204Lys; Cys112Arg) , 2003, Human biology.

[33]  C. Barbagallo,et al.  Two Italian kindreds carrying the Arg136-->Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[34]  H. Schmidt,et al.  A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect. , 2001, Atherosclerosis.

[35]  E. Tai,et al.  Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia. , 2001, Clinical chemistry.

[36]  R. Mahley,et al.  Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. , 2000, The Journal of clinical endocrinology and metabolism.

[37]  I. Rabbone,et al.  Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[38]  R. Mahley,et al.  Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28-->Pro), on lipoproteins and the prevalence of coronary artery disease in whites. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[39]  A. Yamamoto,et al.  Characterization of apolipoprotein E7 (Glu(244)-->Lys, Glu(245)--->Lys), a mutant apolipoprotein E associated with hyperlipidemia and atherosclerosis. , 1999, Journal of lipid research.

[40]  G. Coetzee,et al.  The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[41]  T. V. van Berkel,et al.  Apolipoprotein E Effectively Inhibits Lipoprotein Lipase-mediated Lipolysis of Chylomicron-like Triglyceride-rich Lipid Emulsions in Vitro and in Vivo* , 1996, The Journal of Biological Chemistry.

[42]  R. Mahley,et al.  Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. , 1994, The Journal of biological chemistry.

[43]  G. Coetzee,et al.  Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[44]  P. de Knijff,et al.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. , 1993, American journal of human genetics.

[45]  H. Schuster,et al.  Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100 , 1991, Klinische Wochenschrift.

[46]  R. Mahley,et al.  Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. , 1990, The Journal of biological chemistry.

[47]  G. Assmann,et al.  Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1). , 1990, Journal of lipid research.

[48]  M. Menju,et al.  Analysis of apolipoprotein E7 (apolipoprotein E-Suita) gene from a patient with hyperlipoproteinemia. , 1989, Journal of biochemistry.

[49]  Joseph L. Goldstein,et al.  Internalization-defective LDL receptors produced by genes with nonsense and frameshift mutations that truncate the cytoplasmic domain , 1985, Cell.

[50]  R. Mahley,et al.  A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. , 1984, The Journal of clinical investigation.

[51]  R. Mahley,et al.  Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Mahley,et al.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. , 1982, The Journal of biological chemistry.

[53]  R. Mahley,et al.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. , 1981, The Journal of clinical investigation.

[54]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[55]  M. Krempf,et al.  [Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]. , 2013, Presse medicale.

[56]  L. Iacoviello,et al.  Familial hypercholesterolaemia. , 2001, Lancet.

[57]  W. März,et al.  Molecular basis of type III hyperlipoproteinemia in Germany , 1998, Human mutation.

[58]  G. Béréziat,et al.  Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B‐100 , 1996, Human mutation.

[59]  C. F. Nassar,et al.  Serum lipids and lipoprotein profile in a selected group of normal Lebanese subjects. , 1993, Lebanese Medical Journal.

[60]  C. Junien,et al.  Screening for new mutations in the LDL receptor gene in seven French familial hypercholesterolemia families by the single strand conformation polymorphism method , 1992, Human mutation.

[61]  H. Hobbs,et al.  Molecular genetics of the LDL receptor gene in familial hypercholesterolemia , 1992, Human mutation.

[62]  T. Ogura,et al.  Identification of human apolipoprotein E variant gene: apolipoprotein E7 (Glu244,245----Lys244,245). , 1989, Journal of biochemistry.